Bora Pharmaceuticals Secures $250 Million Manufacturing Deal with GSK, Expanding Long-Term Revenue Visibility

Bora Pharmaceuticals Co., Ltd. (OTCQX: BORAY) has signed a five-year global manufacturing agreement valued at approximately $250 million with GSK plc (NYSE: GSK), strengthening its position as a key contract manufacturing partner to one of the world’s largest pharmaceutical companies. The agreement provides Bora with meaningful revenue visibility while reinforcing its role in the global pharmaceutical supply chain.

Agreement Supports Production of Critical Global Medicines

Under the contract, Bora will continue manufacturing more than 20 commercial pharmaceutical products for GSK at its Mississauga, Canada facility, while leveraging its broader manufacturing network to support additional production needs. The agreement covers more than 335 product variations across major therapeutic areas, including HIV, malaria, migraine, depression, and dermatological treatments.

This long-term commitment ensures continued supply of essential medicines while providing Bora with stable, recurring manufacturing revenue tied to established commercial products.

Strategic Validation of Bora’s Global Manufacturing Platform

The partnership builds on Bora’s 2020 acquisition of the Mississauga facility from GSK, a move that significantly expanded its contract development and manufacturing organization (CDMO) capabilities. Since the acquisition, Bora has strengthened its infrastructure and positioned itself as a scalable manufacturing partner for global pharmaceutical leaders.

For GSK, the agreement ensures reliable production capacity and supply continuity, while allowing the company to focus on drug development and commercialization.

Investor Outlook: Long-Term Contracts Strengthen Growth and Revenue Stability

The $250 million agreement highlights Bora’s expanding role in the fast-growing CDMO market, where pharmaceutical companies increasingly rely on external partners to manage manufacturing. Long-term contracts like this provide predictable revenue streams, reduce business volatility, and validate Bora’s operational capabilities.

As global demand for pharmaceutical manufacturing continues to rise, Bora Pharmaceuticals is well positioned to benefit from additional strategic partnerships and expanding outsourcing trends across the healthcare industry.